e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Asthma: outcomes of clinical trials and cohorts
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Once- vs. twice-daily inhaled therapy in asthma: a network meta-analysis
J. Ora (Rome, Italy), L. Calzetta (Rome, Italy), L. Garzillo (Rome, Italy), M. Matera (Naples, Italy), M. Cazzola (Rome, Italy), P. Rogliani (Rome, Italy)
Source:
International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Session:
Asthma: outcomes of clinical trials and cohorts
Session type:
Thematic Poster
Number:
4244
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Ora (Rome, Italy), L. Calzetta (Rome, Italy), L. Garzillo (Rome, Italy), M. Matera (Naples, Italy), M. Cazzola (Rome, Italy), P. Rogliani (Rome, Italy). Once- vs. twice-daily inhaled therapy in asthma: a network meta-analysis. 4244
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020
Budesonide/formoterol for maintenance and relief
vs.
higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007
Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: A non-inferiority trial
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011
Efficacy of long-term formoterol therapy
vs
as-needed salbutamol use in patients with moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001
Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020
Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009
Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy
Source: Annual Congress 2010 - Management of airway disease
Year: 2010
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta
2
-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
LATE-BREAKING ABSTRACT: ENERGITO: Efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015
Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler
Source: ERJ Open Res 2016: 00106-2015
Year: 2016
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017
Efficacy and safety of combined mometasone furoate/formoterol 100/10μg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy
Source: Eur Respir J 2010; 36: 524-530
Year: 2010
Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002
Fluticasone furoate (FF), a once-daily inhaled corticosteroid (ICS), demonstrates dose-response efficacy in patients symptomatic on non-steroidal asthma therapy
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010
Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020
Effects of budesonide/formoterol combination therapy versus budesonide on airway dimensions in asthma
Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept